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ith the aim to evaluate adenosine 
deaminase serum activity in patients 
with acute myocardial infarction, a 
prospective, observational study were done in 56 patients 
admitted to the central hospital emergency room with a 
diagnosis of acute myocardial infarction; 32 had elevation 
of ST segment in the electrocardiogram, of which 24 un-
derwent thrombolysis therapy and 14 evolved a Q wave. 
Each patient was submitted to a clinical evaluation and 
serum activity of T troponin, creatine kinase, creatine ki-
nase MB isoform of and adenosine deaminase were deter-
mined. Results illustrated that adenosine deaminase serum 
activity was 109.6 ± 8.34 nmol/mL, decreasing after treat-
ment to 82.34 ±7.45 nmol/mL and 81.82 ± 9.40 nmol/mL 
at 24 and 72 hours, respectively, which it was significantly 
related in those patients that displayed no EST in elec-
trocardiogram and received no thrombolytic treatment. In 
these patients adenosine deaminase activity was correlat-
ed with creatine kinase activity. In patients with elevation 
of ST segment (independently of developing a Q wave) 
receiving thrombolytic treatment, the adenosine deami-
nase serum activity remained elevated and unchanged. In 
conclusion: adenosine deaminase levels can be used as 
a molecular marker of the evolution in acute myocardial 
infarction patients receiving no thrombolytic therapy and 
presenting no changes in the ST segment.
KEY WORDS: Adenosine Deaminase, Acute Coronary 
Syndrome, Acute Myocardial Infarction, Creatine kinase.
ardiovascular diseases are responsible for 
30% of deaths worldwide and 80% in 
developing countries1. In Venezuela, Acute 
Myocardial Infarction (AMI) ranks first among causes of 
death from chronic no communicable diseases (21.9%), 
predominantly in males between 40 and 60 years of age2.
AMI is a term used to describe acute necrotic changes in the 
myocardium due to sudden deprivation of coronary blood 
supply (i.e., acute coronary occlusion or hemorrhage), 
which causes hypoxia or anoxia, forcing the cardiomyocyte 
metabolism to change from aerobic to anaerobic3.
During this process, oxygen free radicals and cellular aci-
dosis are generated4 and high-energy phosphates are rap-
idly consumed3. 
Under conditions of tissue damage, endogenous ad-
enosine concentration rapidly raises; furthermore, the 
activation of G protein-coupled adenosine receptors is 
responsible for changes such as vasodilatation, inhibition 
of inflammation, modulation of the sympathetic nervous 
system activity, and protection against the deleterious 
consequences of ischemia-reperfusion5. 
Adenosine levels are regulated by the activity of the en-
zyme adenosine deaminase (ADA), which is a cytosolic 
enzyme of the purine catabolic pathway. This enzyme cat-
alyzes the deamination of adenosine and 2’-deoxyadenos-
ine to produce inosine and 2’-deoxyinosine respectively; 
ammonia is produced as a byproduct in this process6. The 
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physiological role of ADA is not entirely clear; however, 
various studies indicate that ADA activity in plasma of pa-
tients with chronic hypoxia is higher as compared with 
healthy patients, indicating that induction of ADA activ-
ity represents a physiological adaptation to high levels of 
adenosine during hypoxia7. Therefore, we propose that as 
the serum ADA activity is elevated during AMI, its activity 
correlates to the intensity of cellular hypoxia.
The aim of this study was to evaluate the ADA levels in se-
rum samples of patients with AMI and correlate it to EKG 
ST segment changes, Q wave, use of thrombolytic thera-
py, and the serum activity of AMI classic enzyme markers 
(i.e., CK and CKMB) in order to explore the role of ADA as 
a biochemical marker for AMI prognosis.
Population: 56 patients (males and females) older than 
18 years, admitted to the University Central Hospital’s 
emergency room (Barquisimeto, Venezuela) between Sep-
tember 2008 and June 2009, with an AMI diagnosis. All 
patients received a thorough clinical exploration to evalu-
ate the characteristics of the AMI pain (i.e., onset, loca-
tion, duration, radiation, and possible triggering activity) 
and concomitant symptoms and signs: heart rate, blood 
pressure, and a 12-lead electrocardiogram were recorded 
for all patients. Exclusion criteria were: less than 18 years 
of age, sepsis, pneumonia, bronchopneumonia, intestinal 
malabsorption syndrome, asthma and other immune dis-
orders, and signs of dementia and/or psychosis. Patients 
gave informed consent, which was approved by the Eth-
ics Committee of the Centroccidental University “Lisandro 
Alvarado”, Health Sciences School.
Samples: 2-5 ml blood samples (two per patient) taken 
from the antecubital vein at 0, 24, and 72 hours of the 
patient admission  were tested for routine hematology 
parameters as well as for T-troponin and time-dependent 
determination of the CK, CK-MB, and ADA activity.
ADA levels: 5-7 mL of blood without anticoagulant was 
allowed to cloth at room temperature (25°C) for at least 
two hours, centrifuged at 3000 rpm for 30 minutes, and 
the sera stored in Eppendorf’s tubes at -20°C until pro-
cessing. Before testing, samples were slowly thawed and 
the ADA levels measured spectrophotometrically using a 
colorimetric method as described by Giusti and Galanti8.
Statistical analysis: Results are presented as mean ± 
standard error (SE). A one-way ANOVA and Dunnet post-
test were performed to establish whether significant dif-
ferences existed between samples. A p value <0.05 was 
considered statistically significant. Statistical analysis was 
performed using the Graph Pad Prism 4 software.
he population included 36 male and 20 fe-
male, within the range of 31 to 90 years of 
age (average age of 61.52 ± 1.58 years), 
all diagnosed with AMI at admission. 10 patients had 
established history of hypertension and diabetes; 38 pa-
tients had a single antecedent: arterial hypertension (n = 
33), diabetes mellitus (n = 3), and ischemic heart disease 
(n = 2); 10 patients had combined antecedents of arte-
rial hypertension and diabetes and 1 had ischemic heart 
disease and diabetes; 7 patients had no apparent predis-
posing history. The predominant symptom in all these pa-
tients was ischemic chest pain with classical irradiation, 
being the intensity higher in patients that displayed Q 
wave; ischemic pain improved after treatment was initi-
ated. AMIs of anterior location were the most frequently 
(24 for anterior alone and 4 for anterolateral), followed by 
lateral and inferior (13 for each one); 2 patients exhibited 
an extensive AMI which extended more than two cardiac 
walls (for more information see Table I).
The admission EKG demonstrated a ST segment elevation 
in 32 patients, but only 3 had a concomitant Q wave. Of 
those patients admitted with ST segment elevation, but 
no Q wave, 10 developed a Q wave after 24 and 1 patient 
developed it 72 hours after admission. 24 ST segment el-
evation positive patients received thrombolytic therapy. 
The patients with no ST segment elevation and no throm-
bolytic treatment did not develop a Q-wave in the EKG.
CK, CK-MB, and T-troponin serum activities were elevated 
in all patients with clinical diagnosis of AMI. CK and CK-MB 
serum levels decreased significantly and progressively after 
72 hours and the lowering of these enzymes’ level was re-
lated with clinical and EKG improvement (see table II). 
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   Table I. Clinical characteristics of the patient groups
STSE-Q+ STSE-Q- No-STSE
Gender
M 10 13 13
F 3 6 11
Age 61,08 ± 2,83 61,79 ± 2,87 61,54 ± 2,56
Personal 
Antecedents
Hypertension 13 (100 %) 12 (63,16 %) 18 (75 %)
Diabetes 4 (30,77 %) 4 (21,05 %) 6 (25 %)
Ischemic 0 (0 %) 0 (0 %) 3 (12,5 %)
Pain intensity 7,85 ± 0,48* 6,41 ± 0,62 5,33 ± 0,59
Heart rate 82,69 ± 4,65 86,05 ± 4,06 80,13 ± 2,42
Systolic tension 135,3 ± 8,44 128,3 ± 4,30 133,5 ± 4,88
Diastolic tension 79,85 ± 4,89 81,63 ± 2,67 81,38 ± 2,81
Localization
Anterior 4 (30,77 %) 14 (73,68 %) 6 (25 %)
Lateral 4 (30,77 %) 1 (5,26 %) 8 (33,33 %)
Anterolateral 0 (0 %) 0 (0 %) 4 (16,66 %)
Inferior 4 (30,77 %) 4 (21,05 %) 5 (20,83 %)
Extensive 1 (7,69 %) 0 (0 %) 1 (4,17 %)
STSE means ST segment elevation; Q the presence (+) or absence (-) of Q wave. 
The pain intensity was subjectively obtained from the patients in a scale 0 to 10. 
*means p < 0.05 when STSE-Q+ and Non-STSE were compared by Bonferroni’s 
post-test.
All patients diagnosed with AMI had elevated serum levels 
of ADA at admission, which also decreased significantly 
after 24 and 72 hours. The average levels were 109.6 ± 
8.34 nmol/mL at 0 hours, 82.34 ± 7.45 nmol/mL at 24 
hours and 81.82 ± 9.40 nmol/mL at 72 hours.
When performing an analysis of enzyme activity related 
to EKG changes, we noticed that the decrease in these 
enzymes serum activity were statistically significant at 24 
and 72 hours in no ST segment elevation patients and in 
patients that did not received thrombolytic therapy (Fig-
ures 1 and 2). 
ADA activity was positively correlated with the CK activity 
in patients with no ST segment elevation and in patients 
that did not receive thrombolytic treatment. On the other 
hand, in patients with a ST segment elevation that evolved 
to Q-wave, no significant correlation was established be-
tween ADA and CK (Figure 3 and Table 3). CK-MB and 
ADA serum activities were correlated with the sera CK 
and ammonia levels, respectively, for all groups of the pa-
tients, validating the lab methodology. 
In this study, we found no significant correlations among 
the ADA and/or CK-MB serum levels and the patients’ sex 
and/or age.
n this paper we have presented data demonstrat-
ing that ADA serum activity was elevated in patients 
with an AMI diagnosis at the time of hospital admis-
sion; which decreased after 24 and 72 hours of treatment 
onset. The diminished ADA activity was correlated to the 
absence of thrombolytic treatment in patients with no ST 
segment elevation in the EKG; ADA serum activity was 
positively correlated with serum CK activity. 
It has been demonstrated that hypoxic events induce an 
elevation of endogenous adenosine in synaptic and inter-
cellular spaces9, which reflects a high rate of ATP utiliza-
tion and depressed aerobic ATP production as a result of 
hypoxia, leading to elevated levels of AMP, which is con-
verted to adenosine by the action of the 5’-nucleotidase 
enzyme10. The elevation in the level of ADA in serum of 
   Table II. CK, CK-MB and ADA serum activities in ami patients 
   with diferent ekg profiles
 
 TIME
(Hours)
CK 
(UI/dL)
CKMB
(UI/dL)
ADA
(nmol/mL)
STSE-Q+
0 546.3 ± 114.5 116.3 ± 33.14 91.62 ± 11.41
24 612.8 ± 136.3* 119.3 ± 30.67 73.11 ± 9.52
72 414.7 ± 100.0* 56.39 ± 9.783* 89.39 ± 25.46
STSE-Q-
0 400.5 ± 73.23 88.01 ± 13.78 120 ± 19.64
24 430.1 ± 106.4* 79.66 ± 18.57 95.43 ± 17.12
72 286.5 ± 88.52* 40.43 ± 8.112* 101.5 ± 15.04
No-STSE
0 316.4 ± 47.92 76.19 ±13.92 115.4 ± 15.16
24 272.9 ± 35.47* 60.42 ±11.36 75.23 ± 10.18*
72 174.6 ± 25.64* 29.44 ±6.153* 51.12 ± 7.36*
STSE means ST segment elevation; Q the presence (+) or absence (-) of Q wave. *means 
p < 0.05 when 24 and 72 hours are compared with 0 hours.
Figure 1. ADA levels in the serum of AMI patients with different EKG profiles. (A) Pa-
tients with ST segment elevation and Q wave on EKG record; (B) patients with ST seg-
ment elevation and no Q wave; and (C) patients with no ST segment elevation and no 
Q wave. *p < 0.05 for 24 and 72 hours compared to 0 hours.
Figure I
Figure 2. Effect of thrombolytic treatment on the ADA levels in serum of AMI patients. 
(A) No thrombolytic treatment; (B) thrombolytic treatment. *p < 0,05 for 24 and 72 
hours compared to 0 hours; °p < 0.05 for ADA levels at 72 hours for both groups.
Figure II
r2 Pearson’s r p
CK vs CKMB
STSE-Q+ 0.15 0.39 0.01
STSE-Q- 0.16 0.40 0.04
No-STSE 0.15 0.38 0.001
ADA vs CK
STSE-Q+ 0.006 -0.023 0.89
STSE-Q- 0.011 -0.1 0.49
No-STSE 0.11 0.32 0.01
ADA vs CKMB
STSE-Q+ 0.003 -0.057 0.75
STSE-Q- 0.017 0.13 0.38
No-STSE 0.001 0.033 0.8
STSE means ST segment elevation; Q the presence (+) or absence (-) of Q wave.
Table III. Correlation of ADA, CK, and CKMB serum activities in 
ami patients with different ekg profiles 
Figure 3. Correlation between ADA and CK serum levels in AMI patients. (A) patients 
with no ST segment elevation and no Q wave (r2 = 0.11; Pearson’s r = 0.32; p = 0.01). 
(B) AMI patients receiving no thrombolytic treatment (r2 = 0.07; Pearson’s r = 0.26; p 
= 0.02). (C) AMI patients receiving thrombolytic treatment (r2 = 0.02; Pearson’s r = 
-0.13; p = 0.34).  
Figure III
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ischemic patients suggests an adaptive metabolic phe-
nomenon where high levels of adenosine are produced 
during tissue hypoxia.
Adenosine is a nucleoside that counteracts the deleterious 
effects of ischemia as it promotes coronary vasodilatation 
through the activation of A2 receptors11 and decreasing 
the oxygen consumption through activation of A1 recep-
tors12. Also, adenosine is able to attenuate cell damage 
induced by reperfusion13, an effect attributed to mecha-
nisms related to the preservation of ATP, since adenos-
ine stimulates glycolysis by increasing glucose uptake14, 
inhibits the release of norepinephrine acting on A2 pre-
synaptic receptors15,16, and counteracts adrenergic effects 
via A1 receptors17. Furthermore, this nucleoside inhibits 
the activation and adhesion of neutrophils trough A1 and 
A2 receptors, respectively18-20 and inhibits platelet aggre-
gation by acting on A2 receptors21,22; both effects improve 
coronary circulation and counteract ischemia and reperfu-
sion damage by inhibiting the production of free radicals.
Elevation of ADA during hypoxic events has been report-
ed by Eltzschig et al., (2006)7 in pediatric patients with 
chronic hypoxia product of a heart congenital disease. The 
authors, utilizing microarray technology, demonstrated 
that the endothelial ADA gene expression is induced by 
hypoxia. Similarly, Kaul et al., (2006)23 reported that the 
ADA activity and serum malondialdehyde (MDA) were 
elevated in patients with AMI undergoing thrombolytic 
therapy, suggesting that the elevation of ADA is associ-
ated with reperfusion injury in these patients. These re-
sults are consistent with our data, we observed that serum 
ADA levels remained elevated after 24 and 72 hours in 
patients receiving thrombolytic therapy, while decreasing 
significantly in patients that did not receive such therapy. 
The decreased ADA levels in no ST segment elevation pa-
tients’ sera suggest that hypoxic events were completely 
reversed, with no permanent tissue lesion or necrosis. 
ADA can usually be found attached to the endothelial cell 
membrane interacting with CD26 protein7; the ADA-CD26 
interaction can be disrupted by thrombolytic enzymes, re-
leasing ADA into the blood and thus increasing its serum 
levels in those patients receiving thrombolytic treatment. 
The correlation between the serum ADA and CK levels 
in no ST segment elevation patients not received throm-
bolytic treatment, indicates that the elevation of ADA is 
not a phenomenon restricted to heart tissue, but reflects a 
wider occurrence involving other tissues, especially those 
that would be affected by cardiac dysfunction. In this way, 
it has been reported that serum levels of adenosine and 
CK are elevated in patients who had pulmonary edema24; 
taking together these and our data, we propose that the 
elevation of ADA reflects a phenomenon involving pulmo-
nary hypoxia associated to ventricular dysfunction. 
Finally, our findings suggest that in those patients diag-
nosed with AMI, their serum’s ADA level became elevated 
as consequence of myocardial and/or pulmonary hypoxia. 
The level of this enzyme decreased after 24 and 72 hours 
of the supportive treatment onset in no ST segment el-
evation patients that did not receive thrombolytic therapy. 
Because AMI patients with EKG signs of myocardium le-
sion and/or necrosis that received thrombolytic treatment 
maintained high levels of ADA, this enzyme could be con-
sidered a prognostic marker only in those patients with no 
ST segment elevation EKG and receiving no thrombolytic 
therapy. The elevation of serum ADA activity in patients 
receiving thrombolytic treatment could reflect the ADA 
release from its endothelium attachment by the action of 
thrombolytic enzymes.
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